12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Sucampo sales and marketing update

Sucampo launched Rescula unoprostone isopropyl in the U.S. to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. In December, FDA approved an sNDA for the indication. The topical synthetic docosanoid may be used as a first-line agent or concomitantly...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >